Bisphosphonates and lifespan.

Journal Article (Journal Article;Review)

Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases. Following the landmark randomised controlled trial of zoledronate post hip fracture (HORIZON) in which an unexpected survival benefit was found, there has been increasing interest in their potential ability to increase lifespan. This review will consider the clinical evidence for their effect on mortality in both the osteoporosis and non-osteoporosis settings, the latter including studies in intensive care, cancer and cardiovascular disease. Where evidence exists, this review will briefly discuss some of the postulated mechanisms for this survival benefit.

Full Text

Duke Authors

Cited Authors

  • Center, JR; Lyles, KW; Bliuc, D

Published Date

  • December 2020

Published In

Volume / Issue

  • 141 /

Start / End Page

  • 115566 -

PubMed ID

  • 32745686

Electronic International Standard Serial Number (EISSN)

  • 1873-2763

Digital Object Identifier (DOI)

  • 10.1016/j.bone.2020.115566

Language

  • eng

Conference Location

  • United States